{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+4+of+Aluminum+Adjuvant",
    "query": {
      "intervention": "Dose 4 of Aluminum Adjuvant"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 26,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Dose+4+of+Aluminum+Adjuvant&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T13:37:54.507Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02935686",
      "title": "A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ad26.Mos4.HIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Clade C gp140 plus adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Clade C gp140/Mosaic gp140 plus adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "gp140 HIV Bivalent Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2017-03-31",
      "completion_date": "2023-11-22",
      "has_results": true,
      "last_update_posted_date": "2025-05-25",
      "last_synced_at": "2026-09-28T13:37:54.507Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02935686"
    },
    {
      "nct_id": "NCT03480802",
      "title": "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumococcal Infections"
      ],
      "interventions": [
        {
          "name": "V114",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 13™",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PNEUMOVAX™23",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 302,
      "start_date": "2018-07-06",
      "completion_date": "2020-01-17",
      "has_results": true,
      "last_update_posted_date": "2022-05-05",
      "last_synced_at": "2026-09-28T13:37:54.507Z",
      "location_count": 4,
      "location_summary": "Orlando, Florida • West Palm Beach, Florida • Houston, Texas",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03480802"
    },
    {
      "nct_id": "NCT03783130",
      "title": "Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Immunodeficiency Virus Prevention",
        "Human Immunodeficiency Virus (HIV)"
      ],
      "interventions": [
        {
          "name": "VRC-HIVRGP096-00-VP",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Alum Adjuvant",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 16,
      "start_date": "2019-03-07",
      "completion_date": "2020-06-24",
      "has_results": true,
      "last_update_posted_date": "2021-08-12",
      "last_synced_at": "2026-09-28T13:37:54.507Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03783130"
    },
    {
      "nct_id": "NCT06007183",
      "title": "Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chikungunya Virus Infection"
      ],
      "interventions": [
        {
          "name": "CHIKV VLP vaccine booster",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo booster",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bavarian Nordic",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 715,
      "start_date": "2023-08-30",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-08-07",
      "last_synced_at": "2026-09-28T13:37:54.507Z",
      "location_count": 24,
      "location_summary": "Mobile, Alabama • Tempe, Arizona • Melbourne, Florida + 20 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06007183"
    },
    {
      "nct_id": "NCT01666652",
      "title": "A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Dengue Fever"
      ],
      "interventions": [
        {
          "name": "4 µg TDENV-PIV with Alum adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "1 µg TDENV-PIV with AS03B1 adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Phosphate buffered saline",
          "type": "OTHER"
        },
        {
          "name": "1 µg TDENV-PIV with Alum adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "1 µg TDENV-PIV with AS01E1 adjuvant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "U.S. Army Medical Research and Development Command",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "18 Years to 39 Years"
      },
      "enrollment_count": 100,
      "start_date": "2012-09",
      "completion_date": "2017-11",
      "has_results": true,
      "last_update_posted_date": "2019-01-25",
      "last_synced_at": "2026-09-28T13:37:54.507Z",
      "location_count": 1,
      "location_summary": "Silver Spring, Maryland",
      "locations": [
        {
          "city": "Silver Spring",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01666652"
    },
    {
      "nct_id": "NCT00974935",
      "title": "Phase I STEBVax in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Toxic Shock Syndrome Staphylococcal"
      ],
      "interventions": [
        {
          "name": "Aluminum hydroxide",
          "type": "DRUG"
        },
        {
          "name": "STEBVax vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 29,
      "start_date": "2011-02",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2015-06-19",
      "last_synced_at": "2026-09-28T13:37:54.507Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00974935"
    },
    {
      "nct_id": "NCT00296634",
      "title": "H5 Vaccine Alone or With Adjuvant in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Aluminum hydroxide",
          "type": "DRUG"
        },
        {
          "name": "Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 600,
      "start_date": "2006-03",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2010-08-27",
      "last_synced_at": "2026-09-28T13:37:54.507Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • Rochester, New York • Durham, North Carolina + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00296634"
    },
    {
      "nct_id": "NCT00280033",
      "title": "H5 Adult - Chiron Study of Bird Flu Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Aluminum hydroxide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Inactivated Influenza A/H5N1 Vaccine (Chiron)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MF-59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 394,
      "start_date": "2006-02",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2013-09-13",
      "last_synced_at": "2026-09-28T13:37:54.507Z",
      "location_count": 4,
      "location_summary": "Stanford, California • St Louis, Missouri • Cincinnati, Ohio + 1 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00280033"
    },
    {
      "nct_id": "NCT03307915",
      "title": "A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Ad26.Mos4.HIV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MVA-Mosaic",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Clade C gp140 + Mosaic gp140",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 25,
      "start_date": "2018-03-05",
      "completion_date": "2021-11-05",
      "has_results": false,
      "last_update_posted_date": "2025-02-04",
      "last_synced_at": "2026-09-28T13:37:54.507Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03307915"
    },
    {
      "nct_id": "NCT01376765",
      "title": "Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "SARS"
      ],
      "interventions": [
        {
          "name": "Aluminum hydroxide adjuvant (Alhydrogel®)",
          "type": "DRUG"
        },
        {
          "name": "Phosphate buffered saline Placebo",
          "type": "OTHER"
        },
        {
          "name": "Recombinant S protein SARS vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 0,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-15",
      "last_synced_at": "2026-09-28T13:37:54.507Z",
      "location_count": 3,
      "location_summary": "Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01376765"
    }
  ]
}